drugset / Trial / NCT07029529
Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder
Phase 2
Recruiting
80 enrolled
Yale University
National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab
RandomizedParallel-groupQuadruple-blindOther
Summary
For this protocol, the investigators plan to collect data to evaluate apremilast (60mg/day) vs placebo in adults with Alcohol Use Disorders (AUD).
Timeline
- Start
- 2026-05-12
- Primary completion
- 2030-08
- Completion
- 2030-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Apremilast | Small molecule | 60 mg | Oral |